PHVS
NASDAQ HealthcarePharvaris N.V. - Ordinary Shares
Biotechnology
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
๐ Market Data
| Price | $29.44 |
|---|---|
| Volume | 501,920 |
| Market Cap | 1.93B |
| Beta | -2.580 |
| RSI (14-Day) | 56.3 |
| 200-Day MA | $24.99 |
| 50-Day MA | $27.64 |
| 52-Week High | $31.14 |
| 52-Week Low | $14.59 |
| Forward P/E | -9.42 |
| Price / Book | 6.03 |
๐ฏ Investment Strategy Scores
PHVS scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (51/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find PHVS in your text
Paste any article, transcript, or post โ the tool will extract PHVS and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.